Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon beta-1a versus CinnoVex in relapsing-remitting multiple sclerosis
IRCT201612306135N8Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Mar 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple sclerosis (MS) comparing Peginterferon beta-1a with CinnoVex (2 arms). Primary endpoint: Annualized relapse rate. Started Mar 2018; status: completed.
02
Drugs
peginterferon beta-1ainterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT201612306135N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201612306135N8.